Chemoprevention with cyclooxygenase and epidermal growth factor receptor inhibitors in familial adenomatous polyposis patients: mRNA signatures of duodenal Neoplasia

Don A. Delker, Austin C. Wood, Angela K. Snow, N. Jewel Samadder, Wade S. Samowitz, Kajsa E. Affolter, Kenneth M. Boucher, Lisa M. Pappas, Inge J. Stijleman, Priyanka Kanth, Kathryn R. Byrne, Randall W. Burt, Philip S. Bernard, Deborah W. Neklason

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

To identify gene expression biomarkers and pathways targeted by sulindac and erlotinib given in a chemoprevention trial with a significant decrease in duodenal polyp burden at 6 months (P < 0.001) in familial adenomatous polyposis (FAP) patients, we biopsied normal and polyp duodenal tissues from patients on drug versus placebo and analyzed the RNA expression. RNA sequencing was performed on biopsies from the duodenum of FAP patients obtained at baseline and 6-month endpoint endoscopy. Ten FAP patients on placebo and 10 on sulindac and erlotinib were selected for analysis. Purity of biopsied polyp tissue was calculated from RNA expression data. RNAs differentially expressed between endpoint polyp and paired baseline normal were determined for each group and mapped to biological pathways. Key genes in candidate pathways were further validated by quantitative RT-PCR. RNA expression analyses of endpoint polyp compared with paired baseline normal for patients on placebo and drug show that pathways activated in polyp growth and proliferation are blocked by this drug combination. Directly comparing polyp gene expression between patients on drug and placebo also identified innate immune response genes (IL12 and IFNγ) preferentially expressed in patients on drug. Gene expression analyses from tissue obtained at endpoint of the trial demonstrated inhibition of the cancer pathways COX2/PGE2, EGFR, and WNT. These findings provide molecular evidence that the drug combination of sulindac and erlotinib reached the intended tissue and was on target for the predicted pathways. Furthermore, activation of innate immune pathways from patients on drug may have contributed to polyp regression.

Original languageEnglish (US)
Pages (from-to)4-15
Number of pages12
JournalCancer Prevention Research
Volume11
Issue number1
DOIs
StatePublished - Jan 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chemoprevention with cyclooxygenase and epidermal growth factor receptor inhibitors in familial adenomatous polyposis patients: mRNA signatures of duodenal Neoplasia'. Together they form a unique fingerprint.

  • Cite this

    Delker, D. A., Wood, A. C., Snow, A. K., Samadder, N. J., Samowitz, W. S., Affolter, K. E., Boucher, K. M., Pappas, L. M., Stijleman, I. J., Kanth, P., Byrne, K. R., Burt, R. W., Bernard, P. S., & Neklason, D. W. (2018). Chemoprevention with cyclooxygenase and epidermal growth factor receptor inhibitors in familial adenomatous polyposis patients: mRNA signatures of duodenal Neoplasia. Cancer Prevention Research, 11(1), 4-15. https://doi.org/10.1158/1940-6207.CAPR-17-0130